Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

2.

Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.

Health Technol Assess. 2013 Feb;17(7):1-166. doi: 10.3310/hta17070.

3.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
5.

Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.

Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.

Lancet. 2011 Jul 30;378(9789):403-11. doi: 10.1016/S0140-6736(11)60830-1. Review.

PMID:
21764118
6.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
7.

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.

Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X.

PMID:
20452823
8.

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV.

Arch Gen Psychiatry. 2003 Jul;60(7):737-46.

PMID:
12860778
9.

Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis.

Brodaty H, Draper BM, Millar J, Low LF, Lie D, Sharah S, Paton H.

J Clin Psychiatry. 2003 Jan;64(1):63-72.

PMID:
12590626
10.

A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, O'Brien JT.

J Clin Psychiatry. 2004 Jan;65(1):114-9.

PMID:
14744180
11.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators..

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
12.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
13.
14.

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).

Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu LM, Juszczak E; Investigators DART AD..

PLoS Med. 2008 Apr 1;5(4):e76. doi: 10.1371/journal.pmed.0050076.

15.

Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.

Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, Bentham P, Burns A, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Banerjee S.

Br J Psychiatry. 2013 Feb;202:121-8. doi: 10.1192/bjp.bp.112.115212.

16.

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C.

J Clin Psychiatry. 2006 Nov;67(11):1767-75.

PMID:
17196058
17.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
18.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
19.

Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.

Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD.

Am J Geriatr Pharmacother. 2009 Apr;7(2):74-83. doi: 10.1016/j.amjopharm.2009.04.002.

PMID:
19447360
20.
Items per page

Supplemental Content

Support Center